Last reviewed · How we verify

NCT05689697

Induced Physiological Ketosis in Asthenia and\or Decreased Tolerance to Physical and\or Mental Exertion

Status unknown NA Last updated 19 January 2023
What this trial tests

NA trial testing PanTrek in Patient Activation in 88 participants. Status unknown.

Timeline
9 January 2023
Primary endpoint
30 June 2023
15 August 2023

Quick facts

Lead sponsorKetonic Pharm LLC
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment88
Start date9 January 2023
Primary completion30 June 2023
Estimated completion15 August 2023
Sites1 location across Russia

Drugs / interventions tested

Conditions studied

Sponsor

Ketonic Pharm LLC

Who can join

Adults 18 to 65, any sex, with Patient Activation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is evaluating of efficacy of innovative dietary strategy -stimulation of physiological ketosis with Liquid Technology Formula PanTrek, in patients with asthenia and or decreased tolerance to physical and\\or mental exertion. PanTrek is a liquid formula of potassium and magnesium salts of beta-oxibutiric acid, ginsenosides and rosmarinic acid.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Patient Activation

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05689697.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing